Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Rheumatology (Oxford). 2021 Oct 19;60(Suppl 4):iv4-iv15. doi: 10.1093/rheumatology/keab266.
IL-23 is a cytokine member of the IL-12 superfamily. These heterodimeric cytokines offer broad immune regulatory activity with potential effector function in inflammatory arthritis. IL-23 is a pro-inflammatory cytokine secreted by dendritic cells and macrophages. It plays a key role in both innate and adaptive immunity. By promoting and maintaining T cell differentiation into Th17 T cells, IL-23 is a key player in the pathogenesis of rheumatic diseases. Data from pre-clinical IL-23 knockout models show the major importance of IL-23 in development of arthritis. The induction and maintenance of type 17 cells, which secrete IL-17A and other pro-inflammatory cytokines, contributes to local synovial inflammation and skin inflammation in PsA, and perhaps in RA. Commensurate with this, therapeutic strategies targeting IL-23 have proven efficient in PsA in several studies, albeit not yet in RA.
白细胞介素-23（IL-23）是白细胞介素-12 超家族的细胞因子成员。这些异二聚体细胞因子具有广泛的免疫调节活性，在炎症性关节炎中具有潜在的效应功能。白细胞介素-23 是树突状细胞和巨噬细胞分泌的促炎细胞因子。它在先天免疫和适应性免疫中都起着关键作用。通过促进和维持 T 细胞向 Th17 T 细胞的分化，白细胞介素-23 是风湿性疾病发病机制中的关键因素。来自临床前白细胞介素-23 敲除模型的数据表明，白细胞介素-23 在关节炎发展中的重要性。17 型细胞的诱导和维持，其分泌白细胞介素-17A 和其他促炎细胞因子，有助于 PsA 中的局部滑膜炎症和皮肤炎症，也许在 RA 中也是如此。与此相一致的是，针对白细胞介素-23 的治疗策略已被证明在几项 PsA 研究中有效，尽管尚未在 RA 中得到证实。
